Burling Wealth Partners’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.37M Sell
8,507
-3,969
-32% -$661K 0.19% 83
2026
Q2
$2.37M Sell
12,476
-78
-0.6% -$14.7K 0.35% 68
2026
Q1
$2.48M Sell
12,554
-357
-3% -$68.8K 0.4% 61
2025
Q4
$2.37M Buy
12,911
+43
+0.3% +$7.54K 0.37% 63
2025
Q3
$1.97M Sell
12,868
-5,769
-31% -$873K 0.33% 70
2025
Q2
$2.6M Sell
18,637
-4,944
-21% -$693K 0.48% 59
2025
Q1
$3.47M Sell
23,581
-6,151
-21% -$890K 0.73% 46
2024
Q4
$3.9M Buy
+29,732
New +$4.16M 0.8% 39

Other funds holding AZN

Burling Wealth Partners's AZN Position: Q3 2026 in Review

Burling Wealth Partners reduced its AstraZeneca (AZN) stake by 32% in Q3 2026, selling an estimated $661K and leaving 8,507 shares worth $1.37M. The position accounts for 0.19% of the portfolio, ranked #83.

Burling Wealth Partners first reported a position in AZN in Q4 2024 and has held it in 8 quarters since. The position peaked at $3.9M in Q4 2024. 1,446 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Burling Wealth Partners held 8,507 shares of AstraZeneca worth $1.37M as of Q3 2026.
  • Burling Wealth Partners sold 3,969 AstraZeneca shares in Q3 2026, an estimated $661K.
  • AstraZeneca made up 0.19% of Burling Wealth Partners's portfolio in Q3 2026, its #83 holding.
  • Burling Wealth Partners first reported a position in AstraZeneca in Q4 2024 and has held it in 8 quarters since.
  • Burling Wealth Partners's AstraZeneca position peaked at $3.9M in Q4 2024.
  • 1,446 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Burling Wealth Partners's 13F filing for Q3 2026, filed 9 Nov 2026.